ArticleCureus2026
Concurrent Detection of Streptococcus pneumoniae and Herpes Simplex Virus Type 1 (HSV-1) in Cerebrospinal Fluid: Clinical Interpretation Beyond Molecular Positivity.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Herpes simplex virus type 1 (HSV-1) encephalitis and acute bacterial meningitis are severe central nervous system infections associated with significant morbidity. While typically distinct, the increasing use of multiplex polymerase chain reaction (PCR) panels has led to occasional co-detection, creating diagnostic uncertainty. We describe a 44-year-old previously healthy male diagnosed with culture-confirmed pneumococcal meningitis in whom multiplex cerebrospinal fluid PCR also detected HSV-1. The clinical course was complicated by a generalized seizure on hospital day 3 and the development of ventriculitis on day 14, despite negative repeat microbiological assays. Following targeted antibacterial and antiviral therapy, the patient achieved complete neurological recovery. This case highlights the complexity of interpreting molecular results in the setting of severe blood-brain barrier disruption and emphasizes a cautious, chronologically driven approach to management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.